Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-22T01:46:37.108Z Has data issue: false hasContentIssue false
  • English
  • Français

Verapamil therapy in infants with hypertrophic cardiomyopathy

Published online by Cambridge University Press:  19 August 2008

Adrian M. Moran  and
Steven D. Colan
Adrian M. Moran
Affiliation:
Department of Cardiology, Children's Hospital and the Department of Pediatrics, Harvard Medical School, Boston, MA, USA
Steven D. Colan*
Affiliation:
Department of Cardiology, Children's Hospital and the Department of Pediatrics, Harvard Medical School, Boston, MA, USA
*
Dr Steven D Colan, Department of Cardiology, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA. Tel: 617 355 7893, Fax: 617 355 7513; E-mail: Colan@A1tch.harvard.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

We sought to evaluate the saftey and efficacy of acure and chronic treatment with verapamil infanta with hypertrophic cardimyopathy. Prior studies have shown an improvement in adluts with hypertrophiuc cardiomyophathy who were treated with verapamil. Acutely, it reduced the degree of left ventricular outflow tract abstruction. Chronic therapy was associated with an improvement in sysmptoms ans incresed long-term survial. To date, no data are available on the efficacy of this drug in infants with hypertrophic cardiomyopathy. We evaluated prospectively the safety and efficacy of verapamil in infants. The acute and chronic effects of verapamil on infants with an echocardiographic diagnosis of hypertrophic cardiomyopathy were evaluated at a single institution between 1980 and 1994, with long-term follow-up available until 1996. Acute effects of an intravenous bolus of 0.1 mg/kg and infusion at 0.007 mg/kg/min were evaluated, where possible, in the cardiac catheterization laboratory. Oral verapamil at 3–5 mg/kg/day was started after catheterization. Follow-up included serial clinical, echocardiographic and Holter monitoring. A total of 22 patients were studied, 17 having a presumed diagnosis of primary hypertrophic cardiomyopathy including three with Noonan's syndrome. Acute infusion of the drug was well tolerated by all, without adverse electrophysiological effects. Haemodynamic effects were consistent with a negative inotropic action with significant falls in cardiac index (4.6±1.2 to 4.1±0.9 l/min/m2), systolic blood pressure (88±16 to 82±14 mmHg) and gradient across the left ventricular outflow tract (nine patients 48.2±30.4 to 28.4±24.1 mmHg). End-diastolic pressure was unchanged (14.0±6.8 to 13.9±4.7 mmHg). Three patients with primary hypertrophic cardiomyopathy died (two while being treated). In the group with primary hypertrophic cardiomyopathy continuing with long-term treatment, follow-up revealed regression in two, progression in three (two died) and stability in 10. For those treated, there was a trend towards improvement in clinical status. Verapamil is well tolerated acutely in infants with hypertrophic cardiomyopathy. The outcome was considerably better in these patients compared with prior reports, though careful long-term assessment is needed.

Keywords

Infantsverapamilhypertrophiccardiomypathy
Type
Original Articles
Information
Cardiology in the Young , Volume 8 , Issue 3 , July 1998 , pp. 310 - 319
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Maron, BJ, Tajik, AJ, Ruttenberg, HD, Graham, TP, Victroia, BE, Lie, JT, Roberts, WC. Hypertrophic cardiomyopathy in infants: clinical features and natural histroy. Circ 1982; 65 (1): 7–17.CrossRefGoogle Scholar
2.Gilligan, DM, Chan, WL, Joshi, J, Clarke, P, Fletcher, A, Krickler, S, Oakely, CM. A double blind, placebo–controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hyperrtrophic cardiomyopathy. J Am Coll Cardiol 1993; 21 (7): 1672–1679.CrossRefGoogle ScholarPubMed
3.Rosing, DR, Kent, KM, Maron, BJ, Conduit, J, Epstein, SE. Verapamil therapy:a new approch to pharmacologic treatment of hypertrophic cardiomyopathy. Chest 1980; 78: 239–247.Google Scholar
4.Dabrowski, M, Michalak, E, Maurin, A, Rydleweska, SadowskaW, Ruzyllo, W. Results of long–term verapamil treatement of patients with hypertrophic cardiomyopathy. Kardiologia Polska 1989; 32 (Suppl 2): 67–16.Google Scholar
5.Kober, G, Hopf, R, Bubenheirmer, P, Forester, KKunck, KM, Hanrath, P, Vanshausen, KE, Sxhlepper, M, Kaltenbach, M. Long–term treatement of hypertrophic cardiomypathy with verapamil or propranolol in matched pairs of patients: results of a multricicenter study. Zeitschrift fur Kadiologie 1987; 76 (Suppl 3): 113–118.Google Scholar
6.Seiler, C, Schoengeck, M, Turnia, J, Jenni, R, Turina, M, Krayenbuehl, HP. Long–term follow–up of medical versus surgical therapy for hypertrophic cardiomyopathy: a reteospective study. J Am Coll Cardiol 1991; 17(3): 643–645.Google Scholar
7.Pelliccia, F, Cianfrocca, C, Remeo, F, Reale, A. Hypertrophic cardiomyopathy: long–term effects of propranonol versus verapamil in preventing sudden death in ‘low risk’ patients. Cardiovasc Drugs Ther 1990; 4 (6): 1515–1518.CrossRefGoogle Scholar
8.Gibson, R, Driscoll, D, Gillette, P, Hartely, C, Enteman, ML. the comprative electrophysiology and haemodynamic effecte of verapamil in puppies and adult dogs. Dev Pharmacol Ther 1961; 2: 104–116.Google Scholar
9.Porter, CJ, Garson, A Jr, Gillette, Pc. Verapamil: an effective calcium blockimg agent for pediatric patients. Pediatrics. 1983; 71: 748–755.Google Scholar
10.Roguin, N, Shapir, Y, Kaplinsky, EThe Use of Calcium Gluconate Prior to Verapamil in infants With Paroxysmal Supraventricular Tachycardia Springer, New York, 1985: 105.Google Scholar
11.Radford, D. Side effects of verapamil in infants. arch Dis Child 1983; 58: 465–466.Google Scholar
12.Colan, SD, Parness, IA, Spevak, PJ, Sanders, SP. Developmental modulation of myocardial mechanics: age–and growth–related alterations in afterload and contractility. J AM Coll Cardiol 1992; 19: 619–629.Google Scholar
13.Colan, SD, Boutin, C, Castandeda, AR, Wernovsky, G, Status of the left ventricle after arterial switch operation for transposition of the great arteries: haemodynamic and echocardiographic evaluation. J Thorac Cardiovasc Surg 1995; 105: 311–321.CrossRefGoogle Scholar
14.Odemuyiwa, O, McKenna, WJ. Problems in diagnosis and management of hypertrophic cardiomyopathy. Postgard Med J 1991; 67: 713–718.CrossRefGoogle ScholarPubMed
15.Bruch, M, Sharland, M, Shinebourne, E, Smith, G, Patton, M, McKenna, W. Cardiologic abnoralities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 1993; 22: 1189–1192.CrossRefGoogle Scholar
16.Burch, M, Mann, JM, Sharland, M, Shinebourne, EA, Patton, MA, McKenna, WJ. Myocardial disarray in Noonan syndrome. Br Heart J 1992, 68 (6): 586–588.Google Scholar
17.Arai, S, Matsuoka, R, Hirayama, K, Sakurai, H, Tamura, M, Ozawa, T, Kimura, M, Imamura, S, Furutani, Y, Joho, K et al. Missense mutation of the beta–cardiac myosin heavy–chain gene in hypertrophic cardiomyopathy. Am J Med Genet 1995; 58 (3): 267–275.Google Scholar
18.Suda, K, Kohl, T, Kovalchin, JP, Silverman, NH. Echocardiographic predictors of poor outcome in infants with hypertrophic cardiomyopathy. Am J Cardiol 1977, 80: 593–600.Google Scholar
19.Walsh, ERElectrocardiography and introduction to electrophysiologic techniques. In Fyler, D (ed.), Nadas Pediatric Cardiology. Hanley Belfus, Philadelphia, 1992: 137–138.Google Scholar
20.Martin, AB, Garson, A Jr, Perry, J. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J 1994; 12 (1): 64–70.Google Scholar
21.Epstein, SE, Rosing, DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circ 1981; 64 (3): 437–441.CrossRefGoogle ScholarPubMed
22.Somerville, J, Becu, L. Congenital heart disease associated with hypertrophic cardiomyopathy. B Heart J 1978; 40 (9): 1034–1039.CrossRefGoogle ScholarPubMed
23.Guenthard, J, Wyler, F, Fowler, B, Baumgartner, R. Cardiomyopathy in respiratory chain disorders. Arch Dis Child 1995; 72 (3): 223–226.CrossRefGoogle ScholarPubMed
24.Werner, JCSicard, RE, Hansen, TW, Solomon, E, Cowett, RM, Oh, W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 1992; 120: 286–291.Google Scholar
25.Bobele, GB, Ward, KE, Bodensteiner, JB. hyperrophic carediomyopathy during corticottopin thertapy for infantile apasms. A clinical and echocardiographic study. Am J Dis Child 1993, 147 (2): 223–225.Google Scholar
26.Reller, MD, Kaplan, S. Hypertrophic cardiomyopathy in infants of diabetic mothers: an update. Am J Perinatol 1988; 5 (4): 353–358.CrossRefGoogle ScholarPubMed
27.Garson, A Jr. Medicolegal Problems in the management of cardiac arrhythmias in childrena. Pediatrics 1987; 79 (1): 84–88.CrossRefGoogle Scholar
28.TenCate, FJ, Serruys, PW, Mey, S, Roelandt, J. Effects of shortterm administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined haemodynamicultrasonic technique in patients with hypertrophic cardiomyopathy. Circ 1983: 68 (6): 1274–1279.CrossRefGoogle ScholarPubMed
29.Bonow, RO, Ostrow, HG, Cannon, RO, Lipson, LC, Maron, BJ, Kent, KM, Bachatach, SL, Green, MV. effects of verapamil on left ventricular systoloc and diastolic function inpatients with hypertrophic cardiomypATHY: Pressure–valume analysis with a non–imaging scintillation probe. Circ 1983; 68 (5): 1062–1073.Google Scholar
30.Rosing, DR, Kent, KM, Maron, BJ, Epstein, SE. Verapamil therapy: a new aqpproach to the pharmacologic treatement of hypertrophic cardiomyopathy. Circ 1979; 60 (6): 1201–1207.Google Scholar
31.Maron, BJ, Spirotio, P, Wesley, Y, Arce, J. Developemevt and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl L Med 1986M; 315: 610–614.Google Scholar
32.Panza, JA, Maris, TJ, Maron, BJ. Development and determinantrs of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. Circ 1992; 85: 1398–1405.CrossRefGoogle ScholarPubMed
33.chatterjee, K, Raff, G, Anderson, D, Parmely, WW. Hypertrophic cardiomyopathy–therepy with slow channel inhibiting adents. Prog Cardiovasc Dis. 1982; 25 (3): 193–210.Google Scholar
34.Spicer, RL, Rocchini, AP, Crowley, DC, Rosenthal, A. Chronic verapamil therapy in pediatric and young adults patients with hypertrophic cardiomyopathy. Am J Cardiol 1984; 53 (11): 1614–1619.CrossRefGoogle Scholar
35.Meyer, M, de Moor, Mm, Human, D. Hypertrophic cardiomyopathy in infanty and chilhood S Af Med J. 1987: 71 (8): 490–1493.Google Scholar
36.McKenna, WJ, Franklin, RC, Nihoyannopoulos, P, Robinson, KCDeanfield, JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11 (1): 147–153.Google Scholar
37.Maron, BJ, Henry, WL, Clerk, CE, Redwood, DR, Roberts, WC, Epstein, SE. Asymmetric septal hypertophy in childhood. Circ 1976; 53 (1): 9–19.Google Scholar
38.Mckenna, W, Deanfield, J, Faruqui, A, England, D, Oakely, C, Goodwin, J. Prognosis in hypertrophic cardiomyopathy: role of age and climical, electrocardiographic and hemodynamic ceatures. Am J Cardiol. 1981; 47 (3): 532–538.Google Scholar
39.Fiddler, GI, Tajik, AJ, Weidman, W, McGoon, DC, Ritter, DG, Giuliani, ER. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol 1978; 42 (5): 793–799.Google Scholar
40.Maron, BJ, Henry, WL, Clark, CE, Redwood, DR, Roberts, WC, Epstein, SE. Asymetric septal hypertrophy in childhood. Circ. 1976; 53 (1): 9–19.CrossRefGoogle ScholarPubMed
41.Maron, BJ, Bonow, RO, Cannon, RO, Leon, MB, epstein, SE. Hypertrophic cardiomyopathy: interrelarions of clinical manifestastions, pathology and therapy. N EG J Med 1987; 316: 780–789.Google Scholar
42.Maron, BJ, Savage, DD, Wplfson, JK, Epstein, SE. Prognositic singnugiance of 24 hour ambulatory electrocadiographic monitoring in patients with hypertrophic cardiomypathy: a prospective study. Am J Cardiol 1981; 48 (2): 252–257.CrossRefGoogle Scholar
43.Dasvies, MJ, Krikler, DM. Genetic investigation and counselling of families with hypertrophic a cardiomyopathy. Br Herat J 1994; 72 (2): 99–101.Google Scholar